These two companies have moved in opposite directions this year

The biotech industry hasn't performed well this year, even by the standards of the struggling stock market

Let's look at two top cutting-edge healthcare stocks that could make investors richer: Moderna (MRNA 0.70%) and Exelixis (EXEL 4.17%).

Biotech giant Moderna has lost nearly 48% of its value since the beginning of the year. While the company has been a victim of broader economic worries

First, Moderna's shares have fallen so low that they look overvalued, at least by the standards of traditional valuation metrics

Biotech companies can't survive very long unless they have at least a couple of promising programs that can earn regulatory approval

Exelixis is a biotech that focuses on cancer treatments. It is best known for Cabometyx, an oncology product that treats renal cell carcinoma (RCC) and hepatocellular carcinoma

Exelixis is a biotech that focuses on cancer treatments. It is best known for Cabometyx, an oncology product that treats renal cell carcinoma (RCC) and hepatocellular carcinoma